BR Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of bendamustine and rituximab that can be used for the treatment of non-Hodgkin lymphoma (NHL), including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, Waldenstrom macroglobulinemia and lymphoplasmacytic lymphoma, gastric and nongastric mucosa-associated lymphoid tissue (MALT) lymphoma, and nodal and splenic marginal zone lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).

**Synonyms:** - B-R Regimen - BR - Bendamustine Plus Rituximab - Bendamustine and Rituximab (BR) - Bendamustine and Rituximab-abbs (BR) - Bendamustine and Rituximab-arrx (BR) - Bendamustine and Rituximab-blit (BR) - Bendamustine and Rituximab-pvvr (BR) - Bendamustine and Rituximab-rite (BR) - Bendamustine and Rituximab-rixa (BR) - Bendamustine and Rituximab-rixi (BR) - Bendamustine-Rituximab - Bendamustine/Rituximab - Bendamustine/Rituximab Regimen - R-B